Yajuan Qin

Yajuan QIN has had an extensive career in the field of clinical development and research. Yajuan has held multiple roles in various companies, starting with their current position as the Senior Medical Director of Clinical Development at PMV Pharmaceuticals, Inc. Their previous experience includes working as the Director of Clinical Development at ADC Therapeutics, where they led the pivotal phase 2 study for the approval of ZYNLONTA. Yajuan has also worked as an Associate Director and Clinical Scientist at ADC Therapeutics. Prior to that, they served as a Clinical Research Scientist and Senior Medical Writer at Eli Lilly and Company. Yajuan has also held positions at BlueHorizonStemCells, Roche, sanofi-aventis, and Rutgers University - New Jersey Medical School. Overall, Yajuan has a strong background in clinical research, study planning, data review, and protocol analysis.

Yajuan QIN completed a PhD in Pharmacology at Sun Yat-sen University in 2002. Yajuan also holds a Doctor of Medicine (MD) degree from Anhui Medical University.